Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension
Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension
复制标题
DOI：
10.1016/j.cyto.2013.12.013
复制
发表时间：
2014-03-01
期刊：
影响因子：
3.8
通讯作者：
Kaminski, Karol Adam
中科院分区：
文献类型：
--
作者：
Jasiewicz, Malgorzata;Kowal, Krzysztof;Kaminski, Karol Adam
背景：炎症可能在肺动脉高压（PAH）的发病机制中发挥关键作用。我们评估了 PAH 患者血清 sTWEAK 及其清道夫受体 sCD163 的浓度以及 sTWEAK/sCD163 比值。 设计：该研究纳入了 26 名经右心导管检查证实的稳定 PAH 患者和 24 名年龄、性别和体重相匹配的健康志愿者。所有患者均接受经胸超声心动图、心肺运动试验、6分钟步行试验、肺一氧化碳弥散能力（DLCO）测量和静脉血检查。使用 ELISA 试剂盒测定 sTWEAK 和 sCD163 的浓度。结果：与对照受试者相比，PAH 患者的特点是中位血清 sCD163 水平显着较高（1072 vs 890 ng/ml，p = 0.04），而血清 sTWEAK 浓度较低（200 vs 278.1 pg/ml，p = 0.003）。因此，PAH 组的 sTWEAK/sCD163 比率显着较低（0.18 vs 0.33，p = 0.0005）。两组中 sTWEAK 和 sCD163 浓度之间未发现相关性。我们在 PAH 组中观察到峰值 VO2 消耗与 sCD163 浓度之间存在统计学显着的负相关（r = -0.52，p < 0.05），并且与 sTWEAK/sCD163 比率呈正相关（r = 0.45，p < 0.05）。此外，5TWEAK/sCD163 比率与 DLCO 预测值百分比呈正相关（r = 0.42，p < 0.05）。结论：PAH 患者的血清 sTWEAK 和 sCD163 水平发生改变。与单独的 sTWEAK 或 sCD163 相比，sTWEAK/sCD163 比率似乎是 PAH 严重程度的更好指标。 sCD163 或 CD163 与 sTWEAK 之间的相互作用在 PAH 发生或进展中的确切作用及其潜在的预后意义仍有待确定。 (c) 2014 Elsevier Ltd. 保留所有权利。
Background: Inflammation may play a pivotal role in the pathogenesis of pulmonary arterial hypertension (PAH). We evaluated the concentrations of serum sTWEAK, its scavenger receptor sCD163 and sTWEAK/sCD163 ratio in patients with PAH.Design: The study enrolled 26 stable patients with PAH confirmed by right heart catheterization and 24 healthy volunteers matched for age, sex and body weight. All patients underwent transthoracic echocardiography, cardiopulmonary exercise test, 6-min walk test, measurement of lung diffusing capacity for the carbon monoxide (DLCO) and venous blood tests. Concentrations of sTWEAK and sCD163 were determined using ELISA kits.Results: The PAH patients were characterized by significantly higher median serum sCD163 levels (1072 vs 890 ng/ml, p = 0.04) together with lower serum sTWEAK concentrations (200 vs 278.1 pg/ml, p = 0.003) comparing to control subjects. sTWEAK/sCD163 ratio was therefore significantly lower in PAH group (0.18 vs 0.33, p = 0.0005). No correlation was found between sTWEAK and sCD163 concentrations in both groups. We observed statistically significant inverse correlation between peak VO2 consumption and sCD163 concentrations (r = -0.52, p < 0.05) and positive with sTWEAK/sCD163 ratio (r = 0.45, p < 0.05) in PAH group. Moreover, 5TWEAK/sCD163 ratio positively correlated with % of predicted values of DLCO (r = 0.42, p < 0.05).Conclusions: Patients with PAH present altered serum sTWEAK and sCD163 levels. The sTWEAK/sCD163 ratio appears to be a better indicator of the severity of PAH as compared to sTWEAK or sCD163 alone. The exact role of sCD163 or interaction between CD163 and sTWEAK in the initiation or progression of PAH as well as their potential prognostic significance remains to be established. (c) 2014 Elsevier Ltd. All rights reserved.